Physician profile
Kenneth A Lebow
NPI 1902892599
$6,490.97
in general payments reported to CMS, 2019-2025
23 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,357 · 2020: $222 · 2021: $692 · 2022: $634 · 2023: $764 · 2024: $434 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,078.25 | 2019-2024 | Rocklatan, Total30 |
| Johnson & Johnson Surgical Vision, INC. | $1,149.06 | 2019 | |
| Bausch & Lomb Americas INC. | $493.05 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $393.18 | 2019-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $347.73 | 2019-2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.56 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $195.59 | 2022-2023 | Acthar |
| Biotissue Holdings INC. | $193.05 | 2021-2025 | |
| Allergan, INC. | $174.18 | 2020-2022 | |
| Coopervision INC. | $159.55 | 2021-2023 | Paragon Crt |
| Novartis Pharmaceuticals Corporation | $156.39 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $139.86 | 2021 | |
| Harrow Eye, LLC | $138.58 | 2024-2025 | Vevye |
| Glaukos Corporation | $123.27 | 2021 | |
| Astellas Pharma US INC | $121.15 | 2023 | Izervay |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $108.92 | 2025 | |
| Abbvie INC. | $100.72 | 2022 | |
| Oyster Point Pharma, INC. | $44.08 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $35.18 | 2019 | |
| Dompe US, INC. | $30.73 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $22.22 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Optos, INC. | $17.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lebow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.